Hansoh Pharma loses EU authorization for lung cancer drug
AI Summary- Hansoh Pharma said the European Commission revoked authorization for aumolertinib mesylate tablets.
- September 27 marked Hansoh Pharma’s announcement of the EU authorization revocation.
- Hansoh Pharma attributed the decision to a procedural issue in regulatory assessment.